RxDoctor Payments Data

Henry Barraza

Physician Assistant · Los Angeles, CANPI 1417043340

Payments from drug & device makers

$864in general payments, 2019–2025

Across 30 payments — averaging $28.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$170
  • Novo Nordisk$158
  • Nestle Healthcare Nutrition Inc.$118
  • GSK$114
  • Sanofi Pasteur Inc.$73
  • AbbVie$52
  • plus $179 from 8 others

What the payments were for

  • Food & beverage$864100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$864 in reported general payments places this provider in the 70th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$529
Medicare patients
30
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$56,089
FarxigaDapagliflozin Propanediol21$21,776
JanuviaSitagliptin Phosphate28$20,953
EliquisApixaban14$16,437
JanumetSitagliptin Phos/Metformin Hcl15$12,617
TradjentaLinagliptin18$12,325
JardianceEmpagliflozin13$6,959
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,598
Albuterol Sulfate HfaAlbuterol Sulfate43$1,395
Atorvastatin Calcium152$943
Rosuvastatin Calcium47$895
Metoprolol Succinate54$843
Gabapentin42$664
Diclofenac Sodium40$468
Metformin Hcl83$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$158$56,08960 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →